uu.seUppsala universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
Ifakara Hlth Inst, Dar Es Salaam, Tanzania..
Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England.;Mahidol Univ, Mahidol Oxford Trop Med Res Unit MORU, Fac Trop Med, Bangkok 10700, Thailand..
Univ Barcelona, Ctr Invest Saude Manhica Manhica Mozamb & ISGloba, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain..
AFRIMS, Dept Immunol & Med, Bangkok, Thailand..
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Malaria Journal, ISSN 1475-2875, E-ISSN 1475-2875, Vol. 14, artikel-id 359Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up. Methods: Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive. Results: PC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28-63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 > 5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2-12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95-4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44-3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC1/2 since 2007. Conclusions: Several factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measurements to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.

Ort, förlag, år, upplaga, sidor
2015. Vol. 14, artikel-id 359
Nyckelord [en]
Malaria, Parasite clearance, Artemisinin resistance, Drug resistance, Plasmodium falciparum
Nationell ämneskategori
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi Samhällsfarmaci och klinisk farmaci
Identifikatorer
URN: urn:nbn:se:uu:diva-264620DOI: 10.1186/s12936-015-0874-1ISI: 000361426500001OAI: oai:DiVA.org:uu-264620DiVA, id: diva2:865091
Tillgänglig från: 2015-10-26 Skapad: 2015-10-15 Senast uppdaterad: 2018-01-10Bibliografiskt granskad

Open Access i DiVA

fulltext(1918 kB)427 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1918 kBChecksumma SHA-512
a1262a051023a396e4369c4e58ff0e020361b0a347902ed31d12da1d30ccd6cfc1ca1df507d7519d883782e3f8c4a56be3d187c2f5502b9cf5e48d589eb85511
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltext

Personposter BETA

Mårtensson, Andreas

Sök vidare i DiVA

Av författaren/redaktören
Mårtensson, Andreas
Av organisationen
Centrum för klinisk forskning i Sörmland (CKFD)
I samma tidskrift
Malaria Journal
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologiSamhällsfarmaci och klinisk farmaci

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 427 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 2051 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf